Home Events News & Events ISEV Therapeutic Workshop 2015 Programs & Speakers

ISEV Therapeutic Workshop 2015 Programs & Speakers

http://www.isevmeeting.org/uploads/8/6/1/8/8618750/9112280_orig.jpg

 

19 October 2015, Monday (Day 1)

 

 

0800 – 0830

Registration

0830 – 0835

Welcome to the Participants

0835 – 0840

Message from the ISEV president

Jan Lötvall, University of Gotenburg

0840 – 0845

Purpose of ISEV Research Seminars

Marca Wauben, Utrecht University, Executive ISEV Chair for Science and Meeting

0845 – 0915

ISEV position paper on therapeutic EVs

Bernd Giebel, University Hospital Essen

SESSION I

Focus on MSC-EVs

Chair: Lai Ruenn Chai

0915 – 0930

Immune modulatory properties of MSC-EVs

Sai Kiang Lim, A*STAR Institute of Medical Biology

0935 – 0950

Cartilage regeneration with MSC-EVs

Wei Seong Toh, National University of Singapore

0955 – 1010

MSC-EVs in preclinical models of brain tumors

Chaya Brodie, Bar-Ilan University

1015 – 1030

Pigs as translational models for testing MSC exosomes in myocardial infarction and heart failure

Dominique de Kleijn, NUS & UMC Utrecht

1030 – 1100

Tea Break

SESSION II

Various Therapeutic Concepts

Chair: Lim Sai Kiang

1100 – 1115

Reticulocyte-derived exosomes (Rex) immunization in rodent malaria model conferred full and long-lasting protective immunity

Hernando del Portillo, Institute of Global Health

1120 – 1135

Phosphatidylserin to block procoagulant protein assembly –for use as novel anticoagulant

Hang Hubert Yin, University of Colorado Boulder

1140 – 1155

Exosome from plasma of Plasmodium-infected host expressing miRNA inhibit angiogenesis

Yijun Yang, Chinese Academy of Sciences

1200 – 1215

Fusing EVs to engineered lipid carriers produces hybrid vesicles harnessed for the delivery of biomolecules

Joel De Beer, University of Basel

1220 – 1315

Lunch Break

 

SESSION III

Preclinical Models and Clinical Trials

Chair: Jan Lötvall

1315 – 1330

Experiences from canine clinical trials – myxomatous mitral valve disease, randomized controlled CT

Vicky Yang, Tufts University Cummings School of Veterinary Medicine

1335 – 1350

MVs and Exosomes of UC-MSCs are Safe and Effective in Treatment of Patients with Type I DM

Nassar Wael, October Six University

1355 – 1410

EVs and HIV Treatment –Role of NHP models

Kenneth Witwer, Johns Hopkins University School of Medicine

1415 – 1430

DC-EVs and DC-MVs induce immune response of different quality in vivo

Susanne Gabrielsson, Karolinska Institutet

1435 – 1450

Break

SESSION IV

Regulatory requirements

Chair: Mario Gimona

1455 – 1520

Regulatory Aspects on Manufacturing of EV-based therapeutics

Eva Rohde, Paracelsus Medical University Salzburg

1525 – 1620

Q & A to a specialist Health Regulatory Agency

Pharm. Ilona Reischl, Austrian Agency for Health and Food Safety (AGES)

1625 – 1640

Tea Break

Round Table 1

Moderation: Eva Rohde

Notes: RYWY and SST (ASTAR)

1645 – 1815

What are the regulatory frameworks for EVs, what are the requirements?

Do EVs automatically fall under the high-risk definition of investigational new drugs? How can we influence this?

1. Takahiro Ochiya

2. Jang Su Chul

3. Ruenn Chai Lai

4. Joel de Beer

5. John Cadwell

6. Smith Rachel

7. Jan Lötvall

8. Bas van Balkom

9. Vicky Yang

1700

Dinner

 

20 October 2015, Tuesday (Day 2)

 

0830 – 0900

Coffee

SESSION V

Manufacturing

Chair: Ahmed Ibrahim

0900 – 0915

Production of functionally bioactive EVs derived from immortalized neuronal SC lines Randolph Corteling, Reneuron

0920 – 0935

Real time visualization in vitro and in vivo, Biodistribution and Cargo Delivery by EVs – TU – to-TU EV exchange, Focus on effectiveness, toxicity

Charles Lai, National Tsing Hua University

0940 – 0955

The accredited academic GMP manufacturing site for mesenchymal stromal cell-derived EVs at the Paracelsus Medical University Salzburg

Mario Gimona, University Salzburg

1000 – 1030

Tea Break

Round Table 2

Safety & Effectiveness

Moderation: Dominique de Kleijn

Notes: RYWY and SST (ASTAR)

1030 – 1200

What is safe and therapeutic effective EVs in a preclinical setting?

1. Ahmed Ibrahim

2. Chaya Brodie

3. Hernando Del Portillo

4. Susanne Gabrielson

5. Su Chul Jang

6. Wei Seong Toh

7. Wauben

8. Vicky Jang

9. John Sinden

10. Meng Fanyin

11. Murray Broom

1200 – 1300

Lunch Break

Round Table 3

Purification and upscaling

Moderation: Bernd Giebel

Notes: RYWY and SST (ASTAR)

1300 – 1430

Purification and Upscaling: how do we move from the preclinic to the patient?

1. Kevin Buyens

2. Kiyotaka Shiba

3. Randolph Corteling

4. Hernando del Portillio

5. Sai Kiang Lim

6. Nassar Wael

7. Bas van Balkum

8. Danilo Tagle

9. Mario Gimona

10. Marca Wauben

1430 – 1440

Break


SESSION VI

Towards release criteria

Chair: John Sinden

1445 – 1510

Technological challenges of single vesicle based molecular analysis

Marca Wauben, Utrecht University

1515 – 1530

NGS and Characterization of EV RNA from senescent fibroblasts

Hidetoshi Tahara, Hiroshima University Institute of Biomedical & Health Sciences

1535 – 1605

Open for issues like technological limits/chances

1610 – 1630

Tea Break

Wrap Up Session and Discussions

Chair: Takahiro Ochiya

1630 – 1700

Wrap-up RT 1

Eva Rohde, University Salzburg

1700 – 1730

Wrap-up RT 2

Dominique de Kleijn, NUS & UMC Utrecht

1730 – 1800

Wrap-up RT 3

Bernd Giebel, University Hospital Essen

1800 – 1820

Time reserved for alternatives or for questions like: what are the next steps?

1820 – 1830

Concluding Remarks

Sai Kiang Lim and/or Jan Lötvall

1900

Dinner

 

Co-organized by:

 

http://www.a-star.edu.sg/Portals/59/imbLogo.jpg http://foo-lab.com/img/cvri.png

 

Sponsored by:

http://www.archventure.com/images/logos/codiak.gif

http://hpnew.pmu.ac.at/fileadmin/user_upload/presse_downloads/Paracelsus_Logo_rgb_web.jpg https://upload.wikimedia.org/wikipedia/commons/thumb/5/50/Thermo_Fisher_Scientific_logo.svg/1000px-Thermo_Fisher_Scientific_logo.svg.png

http://4965zs3ha2l125fk78zkozo3.wpengine.netdna-cdn.com/wp-content/themes/reneuron/_/images/reneuron-logo-2x.png

Last Updated on Friday, 16 October 2015 11:49